Published in Clin Cancer Res on February 27, 2015
A metabolomic approach to identifying platinum resistance in ovarian cancer. J Ovarian Res (2015) 0.85
Methionine deprivation suppresses triple-negative breast cancer metastasis in vitro and in vivo. Oncotarget (2016) 0.76
Correlation between Polymorphism of TRAIL Gene and Condition of Intervertebral Disc Degeneration. Med Sci Monit (2015) 0.76
High-Level Expression, Purification and Large-Scale Production of l-Methionine γ-Lyase from Idiomarina as a Novel Anti-Leukemic Drug. Mar Drugs (2015) 0.75
Clonostachys rosea demethiolase STR3 controls the conversion of methionine into methanethiol. Sci Rep (2016) 0.75
Effects of ionizing radiation on DNA methylation: from experimental biology to clinical applications. Int J Radiat Biol (2017) 0.75
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med (1999) 9.78
Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest (1999) 7.69
Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature (2012) 3.77
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov (2008) 2.95
Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med (2001) 2.74
AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest (2006) 2.74
Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65 and younger but not older population. Cell Metab (2014) 2.48
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol (2010) 2.43
Defective regulation of autophagy upon leucine deprivation reveals a targetable liability of human melanoma cells in vitro and in vivo. Cancer Cell (2011) 2.24
Overcoming anoikis--pathways to anchorage-independent growth in cancer. J Cell Sci (2011) 1.86
On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene (2012) 1.75
Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res (2003) 1.65
Single amino acid (arginine) deprivation: rapid and selective death of cultured transformed and malignant cells. Br J Cancer (2000) 1.55
High in vivo rates of methionine biosynthesis in transformed human and malignant rat cells auxotrophic for methionine. Proc Natl Acad Sci U S A (1976) 1.50
The effect of replacement of methionine by homocystine on survival of malignant and normal adult mammalian cells in culture. Proc Natl Acad Sci U S A (1974) 1.48
TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest (2008) 1.45
Melanoma-associated antigen genes - an update. Cancer Lett (2010) 1.36
A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res (2010) 1.34
Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol (2009) 1.33
A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res (2010) 1.26
Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels. Clin Cancer Res (2008) 1.18
Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene (2006) 1.13
Methionine dependency and cancer treatment. Cancer Treat Rev (2003) 1.11
Therapeutic tumor-specific cell cycle block induced by methionine starvation in vivo. Cancer Res (1993) 1.11
Methionine requirement and replacement by homocysteine in tissue cultures of selected rodent and human malignant and normal cells. Cancer Res (1978) 1.10
Altered methionine metabolism occurs in all members of a set of diverse human tumor cell lines. J Cell Physiol (1984) 1.08
Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. J Biol Chem (2004) 1.07
αB-crystallin: a novel regulator of breast cancer metastasis to the brain. Clin Cancer Res (2013) 1.02
The metabolic defect of methionine dependence occurs frequently in human tumor cell lines. Biochem Biophys Res Commun (1983) 1.02
Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors. J Clin Oncol (2012) 0.99
Anticancer efficacy in vivo and in vitro, synergy with 5-fluorouracil, and safety of recombinant methioninase. Cancer Res (1998) 0.98
Protein and amino acid restriction, aging and disease: from yeast to humans. Trends Endocrinol Metab (2014) 0.97
Modulation of gene expression in human central nervous system tumors under methionine deprivation-induced stress. Cancer Res (2004) 0.96
Enhanced metastasis suppression by targeting TRAIL receptor 2 in a murine model of triple-negative breast cancer. Clin Cancer Res (2011) 0.95
Expression of the biochemical defect of methionine dependence in fresh patient tumors in primary histoculture. Cancer Res (1993) 0.95
Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice. Clin Cancer Res (1999) 0.94
Methionine depletion enhances the antitumoral efficacy of cytotoxic agents in drug-resistant human tumor xenografts. Clin Cancer Res (2000) 0.94
Nutrient intake and nutritional indexes in adults with metastatic cancer on a phase I clinical trial of dietary methionine restriction. Nutr Cancer (2002) 0.91
Effect of nutritional and enzymatic methionine deprivation upon human normal and malignant cells in tissue culture. Cancer Res (1980) 0.91
Enhanced in vitro selective toxicity of chemotherapeutic agents for human cancer cells based on a metabolic defect. J Natl Cancer Inst (1986) 0.91
The melanoma-associated antigen MAGE-D2 suppresses TRAIL receptor 2 and protects against TRAIL-induced apoptosis in human melanoma cells. Carcinogenesis (2012) 0.84
Human tumors are methionine dependent in vivo. Anticancer Res (1995) 0.82
Induction of caspase-dependent and -independent apoptosis in response to methionine restriction. Int J Oncol (2003) 0.81
Serum methionine depletion without side effects by methioninase in metastatic breast cancer patients. Anticancer Res (1997) 0.81
MAGED2: a novel p53-dissociator. Int J Oncol (2007) 0.79
Methionine restriction reduces the chemosensitivity of central nervous system tumour cell lines. Anticancer Res (2009) 0.79
Quantitative nutritional studies with water-soluble, chemically defined diets. VII. Nitrogen balance in normal and tumor-bearing rats following forced feeding. Arch Biochem Biophys (1959) 0.79
Phase II trial of the association of a methionine-free diet with cystemustine therapy in melanoma and glioma. Anticancer Res (2009) 0.78
Optimal methionine-free diet duration for nitrourea treatment: a Phase I clinical trial. Nutr Cancer (2008) 0.78